Increased Expression of Urokinase Plasminogen Activator and Its Cognate Receptor in Human Seminomas

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Apr 21

PMID 20403162

Citations 8

Authors

Salvatore Ulisse

Enke Baldini

Marcella Mottolese

Steno Sentinelli

Patrizia Gargiulo

Brancato Valentina

Salvatore Sorrenti

Anna Di Benedetto

Enrico De Antoni

Massimino DArmiento

Affiliations

Soon will be listed here.

Abstract

Background: The urokinase plasminogen activating system (uPAS) is implicated in neoplastic progression and high tissue levels of uPAS components correlate with a poor prognosis in different human cancers. Despite that, relative few studies are available on the expression and function of the uPAS components in human seminomas. In the present study we characterized the expression of the urokinase plasminogen activator (uPA), its cognate receptor (uPAR) and the uPA inhibitors PAI-1 and PAI-2 in normal human testis and seminomas.

Methods: The expression of the above genes was evaluated by means of quantitative RT-PCR, western blot, zymographic analysis and immunohistochemistry.

Results: Quantitative RT-PCR analysis of 14 seminomas demonstrated that uPA and uPAR mRNAs were, with respect to control tissues, increased in tumor tissues by 3.80 +/- 0.74 (p < 0.01) and 6.25 +/- 1.18 (p < 0.01) fold, respectively. On the other hand, PAI-1 mRNA level was unchanged (1.02 +/- 0.24 fold), while that of PAI-2 was significantly reduced to 0.34 +/- 0.18 (p < 0.01) fold. Western blot experiments performed with protein extracts of three seminomas and normal tissues from the same patients showed that uPA protein levels were low or undetectable in normal tissues and induced in tumor tissues. On the same samples, zymographic analysis demonstrated increased uPA activity in tumor tissue extracts. Western blot experiments showed that also the uPAR protein was increased in tumor tissues by 1.83 +/- 0.15 fold (p < 0.01). The increased expression of uPA and uPAR was further confirmed by immunohistochemical staining performed in 10 seminomas and autologous uninvolved peritumoral tissues. Finally, variation in the mRNA level of PAI-1 significantly correlated with tumor size.

Conclusions: We demonstrated the increased expression of uPA and uPAR in human seminomas with respect to normal testis tissues, which may be relevant in testicular cancer progression.

Citing Articles

A Role of the TEX101 Interactome in the Common Aetiology Behind Male Subfertility and Testicular Germ Cell Tumor.

Burton J, Wojewodzic M, Rounge T, Haugen T Front Oncol. 2022; 12:892043.

PMID: 35774118 PMC: 9237224. DOI: 10.3389/fonc.2022.892043.

Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours.

Cierna Z, Miskovska V, Roska J, Jurkovicova D, Borszekova Pulzova L, Sestakova Z BMC Cancer. 2020; 20(1):17.

PMID: 31906898 PMC: 6945513. DOI: 10.1186/s12885-019-6496-1.

Tazarotene-Induced Gene 1 (TIG1) Interacts with Serine Protease Inhibitor Kazal-Type 2 (SPINK2) to Inhibit Cellular Invasion of Testicular Carcinoma Cells.

Shyu R, Wang C, Wu C, Wang L, Chen M, Kuo C Biomed Res Int. 2019; 2019:6171065.

PMID: 31886233 PMC: 6899300. DOI: 10.1155/2019/6171065.

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells.

Schmidtova S, Kalavska K, Gercakova K, Cierna Z, Miklikova S, Smolkova B Cancers (Basel). 2019; 11(9).

PMID: 31443351 PMC: 6769487. DOI: 10.3390/cancers11091224.

βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.

Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K BMC Cancer. 2018; 18(1):1062.

PMID: 30390643 PMC: 6215644. DOI: 10.1186/s12885-018-4929-x.

References

BALBONI G, Barni T, Serio M, Vannelli G . Plasminogen activator and inhibin in the human testis. An immunohistochemical investigation. Bull Assoc Anat (Nancy). 1991; 75(228):123-6. View

Skotheim R, Lind G, Monni O, Nesland J, Abeler V, Fossa S . Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res. 2005; 65(13):5588-98. DOI: 10.1158/0008-5472.CAN-05-0153. View

de Bock C, Wang Y . Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2003; 24(1):13-39. DOI: 10.1002/med.10054. View

Looijenga L, Oosterhuis J . Pathogenesis of testicular germ cell tumours. Rev Reprod. 1999; 4(2):90-100. DOI: 10.1530/ror.0.0040090. View

Warde P, Gospodarowicz M, Banerjee D, Panzarella T, Sugar L, Catton C . Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol. 1997; 157(5):1705-9; discussion 1709-10. View

Duffy M . Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem. 2002; 48(8):1194-7. View

Ulbright T . Germ cell neoplasms of the testis. Am J Surg Pathol. 1993; 17(11):1075-91. DOI: 10.1097/00000478-199311000-00001. View

Andreasen P, Kjoller L, Christensen L, Duffy M . The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72(1):1-22. DOI: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. View

Look M, van Putten W, Duffy M, Harbeck N, Christensen I, Thomssen C . Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002; 94(2):116-28. DOI: 10.1093/jnci/94.2.116. View

10.

Kumar S, Baglioni C . Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem. 1991; 266(31):20960-4. View

11.

Esteva F, Hortobagyi G . Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004; 6(3):109-18. PMC: 400674. DOI: 10.1186/bcr777. View

12.

Blasi F, Carmeliet P . uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3(12):932-43. DOI: 10.1038/nrm977. View

13.

Croucher D, Saunders D, Lobov S, Ranson M . Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008; 8(7):535-45. DOI: 10.1038/nrc2400. View

14.

Medcalf R, Stasinopoulos S . The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J. 2005; 272(19):4858-67. DOI: 10.1111/j.1742-4658.2005.04879.x. View

15.

BUNGE R, BRADBURY J . AN EARLY HUMAN SEMINOMA. JAMA. 1965; 193:960-2. DOI: 10.1001/jama.1965.03090110098032. View

16.

Bajou K, Martinez C, Soria C, Lu H, Noel A, Foidart J . Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int J Cancer. 2002; 100(5):501-6. DOI: 10.1002/ijc.10487. View

17.

Okada K, Katagiri T, Tsunoda T, Mizutani Y, Suzuki Y, Kamada M . Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol. 2003; 23(6):1615-35. View

18.

Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U . Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997; 78(1):285-96. View

19.

Konaka H, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M . A human seminoma xenograft model with regional lymph node metastasis. J Urol. 1999; 161(1):342-8. View

20.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View